AI assistant
AMICUS THERAPEUTICS, INC. — Director's Dealing 2018
Jan 4, 2018
31523_dirs_2018-01-04_0cc8e0f9-800d-4df7-bfe8-8a7a306ce987.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: AMICUS THERAPEUTICS INC (FOLD)
CIK: 0001178879
Period of Report: 2018-01-02
Reporting Person: Andrews Kurt J. (SVP, Human Resources)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2018-01-02 | Common Stock | M | 10000 | $14.7191 | Acquired | 44737 | Direct |
| 2018-01-02 | Common Stock | S | 10000 | $14.7191 | Disposed | 34737 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2018-01-02 | Stock Options (right to buy) | $6.13 | M | 10000 | Disposed | 2026-02-01 | Common Stock (10000) | Direct |
Footnotes
F1: The exercise of stock options and subsequent sale of common stock were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2017.
F2: This price is the weighted average purchase price for the transactions reported on this line. The prices for the transactions reported on this line range from $14.12 to $15.16. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.
F3: This price is the weighted average sale price for the transactions reported on this line. The prices for the transactions reported on this line range from $14.12 to $15.16. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.